| abstract |
Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relativento each other in the treatment of disease. In one aspect of the invention, administration ofna nucleoside or other compound reduces the dosage at which a primary drug isnadministered. In another aspect of the invention, an abnormality reflected in increasednresponse in one group of cytokines is treated by administering a nucleoside or otherncompound which increases response in another group of cytokines. In yet another aspectnofthe invention, apatient is prophylactically treated by administering a nucleoside or otherncompound which selectively reduces Th1 activity without significantly reducing Th2nactivity. In yet another aspect of the invention, a nucleoside or other compound isnadministered to a patient at a dose which reduces the patient's GTP pool to a degree thatnselectively reduces one of the Th 1 or Th2 response without significantly reducing the othernresponse. Controlled release dosage forms are particularly contemplated to achieve thatnresult. |